The hypertrophic effect of transforming growth factor-β is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27

Toshiaki Monkawa, Keiju Hiromura, Gunter Wolf, Stuart J. Shankland

研究成果: Article

66 引用 (Scopus)

抄録

Transforming growth factor-β (TGF-β) has both antiproliferative and hypertrophic effects on mesangial cells (MC). However, it is not known if these processes are independent or if they share common signaling pathways. Proliferation and hypertrophy are regulated by specific cell-cycle regulatory proteins, where the cyclin-dependent kinase (CDK) inhibitors inhibit target cyclin-CDK complexes. This study examined whether the growth regulatory effects of TGF-β were determined by the CDK inhibitors p21 and p27. Accordingly, cultured MC from wild type (+/+) and single and double null (-/-) p21 and p27 mice were grown in 5% serum in the presence or absence of TGF-β1 (2 ng/ml). Proliferation ([3H]-thymidine incorporation, cell number, cell cycle) and hypertrophy ([3H]-leucine incorporation, total protein content, forward light scatter) were measured after 24 h, 48 h, and 96 h. TGF-β inhibited proliferation in +/+ and p21/p27 double -/- MC to a similar extent. TGF-β induced hypertrophy in +/+ MC (18.0% increase at 48 h), and to lesser extent in p21 -/- (12.8%) and p27 -/- MC (11.5%) measured by forward light scatter analysis. In p21/p27 double -/-, the hypertrophic effects of TGF-β were significantly reduced (3.9% at 48 h). Similar results were obtained by measuring hypertrophy by total protein and [3H]-leucine incorporation. In conclusion, the CDK inhibitors p21 and p27 are not required for the antiproliferative effects of TGF-β. However, the hypertrophic growth effects of TGF-β are reduced in the absence of both p21 and p27. These data suggest that the regulation of the antiproliferative and hypertrophic effects of TGF-β may be distinct processes.

元の言語English
ページ(範囲)1172-1178
ページ数7
ジャーナルJournal of the American Society of Nephrology
13
発行部数5
DOI
出版物ステータスPublished - 2002
外部発表Yes

Fingerprint

Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinase Inhibitor p27
Transforming Growth Factors
Mesangial Cells
Hypertrophy
Cyclin-Dependent Kinases
Leucine
Light
Cell Cycle Proteins
Cyclins
Growth
Thymidine
Cultured Cells
Cell Cycle
Proteins
Cell Count

ASJC Scopus subject areas

  • Nephrology

これを引用

@article{b51422e7fa0148858af392630ffbd45b,
title = "The hypertrophic effect of transforming growth factor-β is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27",
abstract = "Transforming growth factor-β (TGF-β) has both antiproliferative and hypertrophic effects on mesangial cells (MC). However, it is not known if these processes are independent or if they share common signaling pathways. Proliferation and hypertrophy are regulated by specific cell-cycle regulatory proteins, where the cyclin-dependent kinase (CDK) inhibitors inhibit target cyclin-CDK complexes. This study examined whether the growth regulatory effects of TGF-β were determined by the CDK inhibitors p21 and p27. Accordingly, cultured MC from wild type (+/+) and single and double null (-/-) p21 and p27 mice were grown in 5{\%} serum in the presence or absence of TGF-β1 (2 ng/ml). Proliferation ([3H]-thymidine incorporation, cell number, cell cycle) and hypertrophy ([3H]-leucine incorporation, total protein content, forward light scatter) were measured after 24 h, 48 h, and 96 h. TGF-β inhibited proliferation in +/+ and p21/p27 double -/- MC to a similar extent. TGF-β induced hypertrophy in +/+ MC (18.0{\%} increase at 48 h), and to lesser extent in p21 -/- (12.8{\%}) and p27 -/- MC (11.5{\%}) measured by forward light scatter analysis. In p21/p27 double -/-, the hypertrophic effects of TGF-β were significantly reduced (3.9{\%} at 48 h). Similar results were obtained by measuring hypertrophy by total protein and [3H]-leucine incorporation. In conclusion, the CDK inhibitors p21 and p27 are not required for the antiproliferative effects of TGF-β. However, the hypertrophic growth effects of TGF-β are reduced in the absence of both p21 and p27. These data suggest that the regulation of the antiproliferative and hypertrophic effects of TGF-β may be distinct processes.",
author = "Toshiaki Monkawa and Keiju Hiromura and Gunter Wolf and Shankland, {Stuart J.}",
year = "2002",
doi = "10.1097/01.ASN.0000013162.29833.45",
language = "English",
volume = "13",
pages = "1172--1178",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - The hypertrophic effect of transforming growth factor-β is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27

AU - Monkawa, Toshiaki

AU - Hiromura, Keiju

AU - Wolf, Gunter

AU - Shankland, Stuart J.

PY - 2002

Y1 - 2002

N2 - Transforming growth factor-β (TGF-β) has both antiproliferative and hypertrophic effects on mesangial cells (MC). However, it is not known if these processes are independent or if they share common signaling pathways. Proliferation and hypertrophy are regulated by specific cell-cycle regulatory proteins, where the cyclin-dependent kinase (CDK) inhibitors inhibit target cyclin-CDK complexes. This study examined whether the growth regulatory effects of TGF-β were determined by the CDK inhibitors p21 and p27. Accordingly, cultured MC from wild type (+/+) and single and double null (-/-) p21 and p27 mice were grown in 5% serum in the presence or absence of TGF-β1 (2 ng/ml). Proliferation ([3H]-thymidine incorporation, cell number, cell cycle) and hypertrophy ([3H]-leucine incorporation, total protein content, forward light scatter) were measured after 24 h, 48 h, and 96 h. TGF-β inhibited proliferation in +/+ and p21/p27 double -/- MC to a similar extent. TGF-β induced hypertrophy in +/+ MC (18.0% increase at 48 h), and to lesser extent in p21 -/- (12.8%) and p27 -/- MC (11.5%) measured by forward light scatter analysis. In p21/p27 double -/-, the hypertrophic effects of TGF-β were significantly reduced (3.9% at 48 h). Similar results were obtained by measuring hypertrophy by total protein and [3H]-leucine incorporation. In conclusion, the CDK inhibitors p21 and p27 are not required for the antiproliferative effects of TGF-β. However, the hypertrophic growth effects of TGF-β are reduced in the absence of both p21 and p27. These data suggest that the regulation of the antiproliferative and hypertrophic effects of TGF-β may be distinct processes.

AB - Transforming growth factor-β (TGF-β) has both antiproliferative and hypertrophic effects on mesangial cells (MC). However, it is not known if these processes are independent or if they share common signaling pathways. Proliferation and hypertrophy are regulated by specific cell-cycle regulatory proteins, where the cyclin-dependent kinase (CDK) inhibitors inhibit target cyclin-CDK complexes. This study examined whether the growth regulatory effects of TGF-β were determined by the CDK inhibitors p21 and p27. Accordingly, cultured MC from wild type (+/+) and single and double null (-/-) p21 and p27 mice were grown in 5% serum in the presence or absence of TGF-β1 (2 ng/ml). Proliferation ([3H]-thymidine incorporation, cell number, cell cycle) and hypertrophy ([3H]-leucine incorporation, total protein content, forward light scatter) were measured after 24 h, 48 h, and 96 h. TGF-β inhibited proliferation in +/+ and p21/p27 double -/- MC to a similar extent. TGF-β induced hypertrophy in +/+ MC (18.0% increase at 48 h), and to lesser extent in p21 -/- (12.8%) and p27 -/- MC (11.5%) measured by forward light scatter analysis. In p21/p27 double -/-, the hypertrophic effects of TGF-β were significantly reduced (3.9% at 48 h). Similar results were obtained by measuring hypertrophy by total protein and [3H]-leucine incorporation. In conclusion, the CDK inhibitors p21 and p27 are not required for the antiproliferative effects of TGF-β. However, the hypertrophic growth effects of TGF-β are reduced in the absence of both p21 and p27. These data suggest that the regulation of the antiproliferative and hypertrophic effects of TGF-β may be distinct processes.

UR - http://www.scopus.com/inward/record.url?scp=0036237648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036237648&partnerID=8YFLogxK

U2 - 10.1097/01.ASN.0000013162.29833.45

DO - 10.1097/01.ASN.0000013162.29833.45

M3 - Article

C2 - 11961004

AN - SCOPUS:0036237648

VL - 13

SP - 1172

EP - 1178

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -